MX2023008362A - Composiciones y metodos para el tratamiento de la enfermedad de fabry. - Google Patents

Composiciones y metodos para el tratamiento de la enfermedad de fabry.

Info

Publication number
MX2023008362A
MX2023008362A MX2023008362A MX2023008362A MX2023008362A MX 2023008362 A MX2023008362 A MX 2023008362A MX 2023008362 A MX2023008362 A MX 2023008362A MX 2023008362 A MX2023008362 A MX 2023008362A MX 2023008362 A MX2023008362 A MX 2023008362A
Authority
MX
Mexico
Prior art keywords
methods
fabry disease
compositions
polynucleotides
treating fabry
Prior art date
Application number
MX2023008362A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Cohen
Sean Armour
Christopher Riling
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of MX2023008362A publication Critical patent/MX2023008362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023008362A 2021-01-14 2022-01-13 Composiciones y metodos para el tratamiento de la enfermedad de fabry. MX2023008362A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137235P 2021-01-14 2021-01-14
US202163264356P 2021-11-19 2021-11-19
PCT/US2022/070184 WO2022155665A1 (en) 2021-01-14 2022-01-13 Compositions and methods for treating fabry disease

Publications (1)

Publication Number Publication Date
MX2023008362A true MX2023008362A (es) 2023-10-04

Family

ID=82448637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008362A MX2023008362A (es) 2021-01-14 2022-01-13 Composiciones y metodos para el tratamiento de la enfermedad de fabry.

Country Status (12)

Country Link
US (1) US20240301380A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277988A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504611A (cg-RX-API-DMAC7.html)
KR (1) KR20230131246A (cg-RX-API-DMAC7.html)
AU (1) AU2022207185A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208153A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002015A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023010599A2 (cg-RX-API-DMAC7.html)
IL (1) IL304273A (cg-RX-API-DMAC7.html)
MX (1) MX2023008362A (cg-RX-API-DMAC7.html)
PE (1) PE20240915A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022155665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022381751A1 (en) * 2021-11-03 2024-05-16 Sangamo Therapeutics, Inc. Methods for use of viral vector constructs for the treatment of fabry disease
AU2024241509A1 (en) * 2023-03-20 2025-09-25 Spark Therapeutics, Inc. Ppt1 gene therapy
CN117551636B (zh) * 2023-04-30 2024-11-08 四川至善唯新生物科技有限公司 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
US20240360431A1 (en) * 2023-04-30 2024-10-31 Sichuan Real&Best Biotech Co., Ltd. Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
WO2025264565A1 (en) * 2024-06-17 2025-12-26 Spark Therapeutics, Inc. Promoters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
JP7114485B2 (ja) * 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
KR102712926B1 (ko) * 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
SG11202011191WA (en) * 2018-05-16 2020-12-30 Spark Therapeutics Inc Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
BR112021009913A2 (pt) * 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
US12163425B2 (en) * 2020-03-13 2024-12-10 Baker Hughes Oilfield Operations Llc Automated geosteering based on a distance to oil-water contact

Also Published As

Publication number Publication date
CL2023002015A1 (es) 2024-03-08
CA3208153A1 (en) 2022-07-21
EP4277988A4 (en) 2024-12-11
CO2023010599A2 (es) 2023-09-18
AU2022207185A9 (en) 2024-07-25
AU2022207185A1 (en) 2023-07-13
JP2024504611A (ja) 2024-02-01
PE20240915A1 (es) 2024-04-30
WO2022155665A1 (en) 2022-07-21
EP4277988A1 (en) 2023-11-22
US20240301380A1 (en) 2024-09-12
IL304273A (en) 2023-09-01
KR20230131246A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
CL2023002015A1 (es) Composiciones y métodos para el tratamiento de la enfermedad de fabry.
DK580385D0 (da) Gaerstammer, der danner cellulolytiske enzymer og fremgangsmaade til fremstilling deraf
MX2023008801A (es) Composiciones y metodos para tratar angioedema hereditario.
MX2022002834A (es) Polipeptidos con actividad beta-glucanasa y polinucleotidos que los codifican.
PH12020551957A1 (en) Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same
JP2009509555A5 (cg-RX-API-DMAC7.html)
DE60022313D1 (de) Alternansucrase-kodierende nukleinsäure moleküle
Pryor Free radicals in biological systems
SG2013021217A (en) Production of high mannose proteins in plant culture
AU2002311989A1 (en) Methods and materials for the production of organic products in cells of $i(candida) species
HUT77469A (hu) Eljárás molekulák bevitelére a sejtcitoszolba
MX2009011751A (es) Produccion de proteinas de alto contenido de manosa en cultivo de plantas.
EP2284184A3 (en) Bacillus YvmA inactivation
BRPI0408735A (pt) polinucleotìdeo isolado, construção de ácido nucléico, célula transgênica, organismo transgênico, vegetal transgênico, método para produzir um vegetal transgênico, método para expressar um polinucleotìdeo de interesse em uma célula, e método para co-expressar dois polinucleotìdeos de interesse em uma célula
BR112022023067A2 (pt) Elastômeros de poliuretano sem isocianato e composições compreendendo tais elastômeros
SI1670779T1 (sl) Postopki za pripravo 3-metilamino-1-(tien-2-il)-propan ola
MX2008000200A (es) Polinucleotidos que codifican enzimas que modifican el isoprenoide y sus metodos de uso.
DK1373480T3 (da) Ukoblede produktive og katabolske værtscellebaner
ZA202210127B (en) Codon optimized gla genes and uses thereof
Tsang et al. Preparation of adenosine 5′-phosphosulfate (APS) from adenosine 3′-phosphate 5′-phosphosulfate (PAPS) prepared by an improved procedure
BRPI0507934A (pt) plantas modificadas com mini-cromossomas
MX2022010284A (es) Glicosiltransferasas, polinucleotidos que codifican las mismas y metodos de uso.
WO2023201354A3 (en) Elements for de-targeting gene expression in liver
WO2025137275A8 (en) Novel cas nucleases and polynucleotides encoding the same
WO2005100587A3 (en) Methods for obtaining optically active epoxides and vicinal diols from 2,2-disubstituted epoxides